EU countries approve Striverdi Respimat (Boehringer) for COPD
Three EU countries have approved the use of Striverdi Respimat (olodaterol), from Boehringer Ingelheim, for patients with Chronic Obstructive Pulmonary Disease (COPD). First approvals of Striverdi Respimat in United Kingdom, Denmark and Iceland are based on data from the Phase III clinical trial programme involving more than 3,500 patients with moderate to very severe COPD (GOLD spirometric level 2-4).
This showed that, compared to usual care alone, lung function improvements with once-daily Striverdi Respimat translated into significant improvements in patients' quality of life, as measured by the reduction in their St George's Respiratory Questionnaire (SGRQ) total score. Following the positive outcome of the review process, further national approvals in EU/EEA countries are expected to follow.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.